Short Interest in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Decreases By 50.7%

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a large drop in short interest in December. As of December 15th, there was short interest totalling 59,600 shares, a drop of 50.7% from the November 30th total of 120,900 shares. Approximately 0.2% of the shares of the stock are short sold. Based on an average trading volume of 149,700 shares, the days-to-cover ratio is currently 0.4 days.

Bolt Biotherapeutics Trading Up 1.5 %

Shares of BOLT stock traded up $0.01 during trading hours on Friday, hitting $0.52. 257,086 shares of the company’s stock traded hands, compared to its average volume of 167,273. The stock has a market cap of $19.83 million, a PE ratio of -0.30 and a beta of 0.93. The stock’s 50 day simple moving average is $0.59 and its 200 day simple moving average is $0.66. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. Bolt Biotherapeutics has a 12 month low of $0.48 and a 12 month high of $1.56.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.04). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The company had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.02 million. On average, sell-side analysts anticipate that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Bolt Biotherapeutics in a report on Wednesday, November 13th. Five analysts have rated the stock with a hold rating, According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.50.

Institutional Trading of Bolt Biotherapeutics

An institutional investor recently raised its position in Bolt Biotherapeutics stock. FMR LLC grew its position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 33.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 115,386 shares of the company’s stock after purchasing an additional 28,773 shares during the quarter. FMR LLC owned approximately 0.30% of Bolt Biotherapeutics worth $75,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.